Lysophosphatidic acid receptor agonists and antagonists (WO2010051053)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 2, 2011, Pages 281-286

  Parrill, Abby L ^a  

^a University of Memphis   (United States)

Author keywords

Cancer; chemoprotection; LPA2 receptor; lysophosphatidic acid; radioprotection

Indexed keywords

1, 1 DIFLUOROPENTADECYL PHOSPHONIC ACID; ANTINEOPLASTIC AGENT; DICARBOXYLIC ACID; DICARBOXYLIC ACID DERIVATIVE; FATTY ACID; GLYCEROL; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR AGONIST; LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST; OLEOYLTHIOPHOSPHATE; PHOSPHORIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CRYPT CELL; IRRADIATION; NEOPLASM; NONHUMAN; RADIOTHERAPY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOPROTECTION; HUMANS; MICE; PATENTS AS TOPIC; RECEPTORS, LYSOPHOSPHATIDIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952969747     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.539206     Document Type: Article

References (29)

1. Tigyi G, Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 2010;161(2):241-70
2. van Meeteren LA, Ruurs P, Christodoulou E, et al Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 2005;280(22):21155-61 (Pubitemid 40805676)
3. Ye X, Ishii I, Kingsbury MA, et al Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta 2002;1585(2-3):108-13 (Pubitemid 36092074)
4. Radeff-Huang J, Seasholtz TM, Matteo RG, et al G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 2004;92(5):949-66 (Pubitemid 44264244)
5. Deng W, Shuyu E, Tsukahara R, et al The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 2007;132(5):1834-51
6. E S, Lai YJ, Tsukahara R, et al Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect. J Biol Chem 2009;284(21):14558-71 This publication provides insight into the mechanism of LPA2-mediated cytoprotection.
7. Chun JJM, Weiner JA, Wickens PL, et al Methods using a lysophosphatidic acid receptor agonist for promoting survival of myelin-producing cells. (The Regents of the University of California, USA; Allelix Biopharmaceuticals Inc.). Application: WO2000009139, 37pp; 2000
8. Kanan E, Kondo H, Shishikura J, et al benzyl-12b-methyl-1,2,3,4,6,7,12, 12boctahydroindolo[ 2,3-a]quinolizine derivatives as LPA receptor agonists. (Astellas Pharma Inc., Japan). Application: JP2008297278, 15pp; 2008
9. Gududuru V. LPA Receptor Agonists and Antagonists. RXBIO, Inc.: Application: WO2010051053, 66pp; 2010
10. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: Critical new players in breast cancer initiation and progression. Br J Cancer 2010;102(6):941-6
11. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3(8):582-91 (Pubitemid 37328830)
12. Murph M, Mills GB, Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007;9(28):1-18 (Pubitemid 47617558)
13. Pua TL, Wang FQ, Fishman DA. Roles of LPA in ovarian cancer development and progression. Future Oncol 2009;5(10):1659-73
14. Ramachandran S, Shida D, Nagahashi M, et al Lysophosphatidic acid stimulates gastric cancer cell proliferation via ERK1-dependent upregulation of sphingosine kinase 1 transcription. FEBS Lett 2010;584(18):4077-82
15. Jeon ES, Lee IH, Heo SC, et al Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism. Biochim Biophys Acta 2010;1801(11):1205-13
16. Durgam GG, Virag T, Walker MD, et al Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem 2005;48(15):4919-30 (Pubitemid 41033134)
17. Virag T, Elrod DB, Liliom K, et al Fatty alcohol phosphates are subtype-selective agonists and antagonists of LPA receptors. Mol Pharmacol 2003;63(5):1032-42 This paper represents the first report of the LPA receptor-mediated functions of compounds claimed in the current application. (Pubitemid 36529921)
18. Hasegawa Y, Erickson JR, Goddard GJ, et al Identification of a phosphothionate analogue of lysophosphatidic acid as a selective agonist of the LPA3 receptor. J Biol Chem 2003;278(14):11962-9 (Pubitemid 36800170)
19. Xu Y, Aoki J, Shimizu K, et al Structure-activity relationships of fluorinated lysophosphatidic acid analogues. J Med Chem 2005;48(9):3319-27 (Pubitemid 40628050)
20. Murakami-Murofushi K, Shioda M, Kaji K, et al Inhibition of eukaryotic DNA polymerase alpha with a novel lysophosphatidic acid (PHYLPA) isolated from myxoamoebae of Physarum polycephalum. J Biol Chem 1992;267(30):21512-17
21. Miller DD, Tigyi G, Durgam GG, et al LPA Receptor Agonists and Antagonists and Methods of Use, U.S.P.a.T. Office. The University of Tennessee Research Foundation: US7217704; 2007 . This is the pre-existing patent supported by the same in vivo data as the current application.
22. Kosanam H, Ma F, He H, et al Development of an LC-MS/MS assay to determine plasma pharmacokinetics of the radioprotectant octadecyl thiophosphate (OTP) in monkeys. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878(26):2379-83 . This paper describes the pharmacokinetics of orally-administered oleoyl thiophosphate in primates to extend the significance of the claimed radioprotection from rodents to an organism more relevant to human clinical use.
23. Xu Y, Qian L, Prestwich GD. Synthesis of monofluorinated analogues of lysophosphatidic acid. J Org Chem 2003;68(13):5320-30 (Pubitemid 36750207)
24. Xu Y, Qian L, Pontsler AV, et al Synthesis of difluoromethyl-substituted lysophosphatidic acid analogues. Tetrahedron 2004;60(1):47-53
25. Xu Y, Tanaka M, Arai H, et al Alkyl lysophosphatidic acid and fluoromethylene phosphonate analogs as metabolically-stabilized agonists for LPA receptors. Bioorg Med Chem Lett 2004;14(21):5323-8 (Pubitemid 39348922)
26. Jiang G, Xu Y, Fujiwara Y, et al Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem 2007;2(5):679-90
27. Heise CE, Santos WL, Schreihofer AM, et al Activity of 2-substituted LPA analogs at LPA receptors: Discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol 2001;60(6):1173-80 (Pubitemid 33144887)
28. Santos WL, Heasley BH, Jarosz R, et al Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett 2004;14(13):3473-6 (Pubitemid 38737149)
29. Murakami-Murofushi K, Kobayashi S, Onimura K, et al Selective inhibition of DNA polymerase-alpha family with chemically synthesized derivatives of PHYLPA, a Unique Physarum lysophosphatidic acid. Biochim Biophys Acta 1995;1258(1):57-60